Acer Therapeutics — Investor Presentation (February 2020)
40 slides from Acer Therapeutics's investor presentation, Feb 24, 2020
Slide 1: Corporate Presentation February 2020
Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Critical Unmet Medical Needs Corporate Presentation February 2020 Nasdaq: ACER Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Corporate Overview
Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with critical unmet medical needs Headquartered: Newton, MA Headcount: 18 Founded: December 2013 Public: September 2017 Cash: $
Slide 4: Executive Leadership Team
Executive Leadership Team Chris Schelling CEO & Founder 20 years; strategic commercial development & orphan Will Andrews, MD Chief Medical Officer 20 years; clinical development, medical affairs & orphan M.D. Yale University School of Medicine Harry Palmin Chief Operating & Financial Officer 25 year
Slide 5: Investment Highlights
Investment Highlights Acer’s pipeline includes three clinical-stage product candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a taste-masked, immediate release formulation of sodium
Slide 6: Clinical Pipeline
Program / Indication Novel MOA / Unique Characteristics Phase 1 Phase 2 Phase 3 NDA Market EDSIVOTM (celiprolol) vascular Ehlers-Danlos syndrome (COL3A1+) Induces vascular dilatation and smooth muscle relaxation ACER-001 (taste-masked, immediate-release form of sodium phenylbutyrate) Urea Cycle Diso
Slide 7: EDSIVO unique pharmacological profile
EDSIVO™ has a unique pharmacological profile β2 and β3 adrenergic receptor agonist; selective β1 and ⍺2 adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS) EDSIVO’s™ potential beneficial effects in vEDS thought to be through vascular dilatation and smooth muscle relaxa
Slide 8: EDSIVO: CRL and Next Steps
Received CRL from FDA on June 24, 2019 The CRL stated it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS Submitted Formal Dispute Resolution Request (FDRR) to the Office of New Drugs (OND) in
Slide 9: EDSIVO FDRRs: Recent Historical Perspective
In 2016, FDA published that from 2003-2014, of the 140 appeals accepted, 16% were granted and 84% denied According to HPM, these “denials” were most often “wins” While approval was not provided based on the previous NDA submission, the company was given a more favorable path forward to approval than
Slide 10: Vascular Ehlers-Danlos Syndrome (vEDS)
Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Gastrointestinal Uterine Autosomal dominant (50%); spontaneous mutations (50%) Diagnosed by clinical symptom
Slide 11: EDSIVO Unique Mechanism of Action
Cardiology in Review 2017;25: 247–253. *Hypertension 2003 Nov;42(5):1004-13. EDSIVO™ has a unique pharmacological profile: β2 and β3 adrenergic receptor agonist Selective β1 and ⍺2 adrenergic receptor antagonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Activates
Slide 12: EDSIVO BBEST Clinical Trial Efficacy
Efficacy: 64% reduction in the average risk of fatal or nonfatal cardiac or arterial events in EDSIVO™ patients vs. control group over mean follow-up of 47 months 76% average reduction in risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group 69% reduction
Slide 13: EDSIVO Efficacy: Survival Outcomes
Efficacy: Between 2000 and 2017, 144 patients (median age at diagnosis 34.5 years; 100% COL3A1+) were included in this study (A) Patients not treated with celiprolol had a significantly worse survival outcome than treated patients: Overall survival was 80.7% (95% CI: 67.8% to 93.6%) in those treated
Slide 14: EDSIVO U.S. vs. French vEDS Patients
EDSIVO™ U.S. vs. French vEDS Patients Pepin Genet Med. 2014 Dec;16(12):881-8. Frank et al., J Am Coll Cardiol. 2019 Apr 23;73(15):1948-1957. Median Survival: 51 years (46 y.o. males; 54 y.o. females) U.S. vEDS Natural History 1,231 patients (>90% COL3A1+; 630 index / 601 relatives) French vEDS Popul
Slide 15: Antihypertensive use in U.S. vEDS patients
Background: No currently approved medications to treat vEDS There is no evidence supporting the use of antihypertensive medications in vEDS Methods: Retrospective analysis of U.S. insurance claims identifying vEDS patients 2014-2017 Patient data stratified based on claims for patients taking antihyp
Slide 16: ACER-001 taste-masked sodium phenylbutyrate
Small molecule with unique MOAs in various disorders UCDs: NaPB is a prodrug of phenylacetate, a NH4+ scavenger MSUD: NaPB is an allosteric inhibitor of BCKD kinase UCDs: A group of metabolic genetic diseases that lead to toxic build-up of NH4+ UCDs: Currently treated with RAVICTI®, BUPHENYL®, AMMON
Slide 17: ACER-001 UCDs: Clinical Manifestations
Newborns with severe urea cycle disorders become catastrophically ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a
Slide 18: ACER-001 UCDs: Unmet Need
ACER-001 UCDs: Unmet Need BUPHENYL®: Foul odor and foul/bitter taste; considered unpalatable* 64% of patients reported it is difficult to take because of taste Physicians reported that 25-33% of patients were prescribed less than target dose due to tolerability Only 25% of patients indicated that th
Slide 19: ACER-001: Differentiation
Phenylbutyrate Formulations ACER-001* RAVICTI® BUPHENYL® Efficacy / Safety in UCDs ✓ ✓ ✓ Palatability / Compliance ✓ ✓ ✘ ** Pricing (Per Patient Per Year) TBD, likely near BUPHENYL $158k-$1.2M*** $204k-$402k*** Formulation Multi-Particulate (Sachet) Oil (Tablespoons) Powder/Tablets (up to 40 tablets
Slide 20: ACER-001 Bioequivalence and Taste Trials
Pivotal bioavailability and bioequivalence (BE) trial: Part A: single-center, single-blind, randomized, single-dose crossover study designed to evaluate bioavailability of three different oral suspension formulations of ACER-001 compared to BUPHENYL® in 20 healthy adult subjects Successfully complet
Slide 21: ACER-001 UCDs: Bioequivalence Trial Results (Part A)
ACER-001 UCDs: Bioequivalence Trial Results (Part A) PBA = phenylbutyrate; PAA = phenylacetate PK Plasma Concentration (PBA) ACER-001 Buphenyl -100 -50 0 50 100 150 200 250 300 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 PK Plasma Concentration (PAA) Lab Name Parameter Geometric Mean Difference Lower 90%
Slide 22: UCDs: Market Opportunity
Target existing Rx market share in UCDs Currently 1,100 patients diagnosed with ~600 patients on Rx therapy* 2018 U.S. revenue for Ravicti® & Buphenyl® = $248.4M Goal: transition patients from Ravicti® & Buphenyl® to ACER-001 and capture a portion of new UCDs Rx “Transition” Value Story: A cost-effe
Slide 23: ACER-001 Maple Syrup Urine Disease
MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of
Slide 24: ACER-001 MSUD: Clinical POC
ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at BCM – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Results: NaPB demonstrated stati
Slide 25: MSUD: Market Opportunity
About 1,000 MSUD patients in the U.S., ~3,000 WW* 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380 Ashkenazi Jewish population; incidence of 1/26,000 No treatments currently approved for MSUD Early treatment may help reduce the rate of neuropsychological comorbidities and optimize g
Slide 26: ACER-001: Exclusivity / IP
ACER-001 ACER-001: Exclusivity / IP Filed formulation patent application (filed Oct. 2016) Issued patents (US/EP): “Methods of modulation of branched chain acids and uses thereof” [US PATENT NO. 10,092,532] in MSUD Exclusive license rights from Baylor College of Medicine UCDs: 505(b)(2) application
Slide 27: Osanetant NK3 receptor antagonist
Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus iVMS: Induced Vasomotor Symptoms where Hormone Replacement Therapy (HRT) is likely contrain
Slide 28: Osanetant History
Acer acquired worldwide rights to osanetant from Sanofi in December 2018 Osanetant (SR142801) was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia Clinical and laboratory safety results are available from 21 completed Phase 1 and
Slide 29: Osanetant Vasomotor Symptoms (VMS): Overview
VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) While VMS associated with menopause can often be treated with hormone replacement therapy (HRT), there are patients who experience VMS who
Slide 30: Osanetant Induced Vasomotor Symptoms (iVMS)
Osanetant Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 y
Slide 31: Osanetant iVMS: The Unmet Need
Osanetant iVMS: The Unmet Need Induced vasomotor symptoms (iVMS) are well documented with the use of hormonal cancer therapies and certain surgical procedures Symptoms such as hot flashes can appear immediately and be severe Traditional HRTs are usually contraindicated Non-adherence to therapy can b
Slide 32: NK3 Receptor (Neurokinin B)
Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d
Slide 33: Osanetant VMS: Mechanism of Action
Neurons in the arcuate nucleus of the hypothalamus that express kisspeptin and neurokinin B (Kiss1ARH neurons) are candidates for mediating hot flashes because they are negatively regulated by sex hormones Transient activation of Kiss1ARH neurons following sex-hormone withdrawal contributes to the o
Slide 34: NK3R Antagonist Clinical POC in VMS (Fezolinetant)
Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017 Fezolinetant is a NK3R antagonist being developed by Astellas At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Daily Hot Flash Frequency Reported a
Slide 35: NK3R Antagonist Clinical POC in VMS (Pavinetant)
Osanetant NK3R Antagonist Clinical POC in VMS Prague J., et al. Menopause. 2018 Aug;25(8):862-869. Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo % change from baseline Hot flash frequency Hot flash severity Placebo MLE4901 Hot flash bother Hot flash interference A B C
Slide 36: Osanetant: Clinical Development Plan
Acer is partnering with a leading university to design & conduct a clinical trial to evaluate osanetant in various patient populations with iVMS These include patients with medically or surgically iVMS (may include any/all of the following): Women who are BRCA+ and have had a PBSO Men with HR+ Prost
Slide 37: Osanetant: Competitive Landscape
Osanetant Program / Company Indication MOA Status VERU-944 (Veru) iVMS in PC on ADT ER agonist Ph 2 Q-122 (Que Oncology) iVMS in BC on Tamoxifen or AIs CRCX4 modulator Ph 2 Fezolinetant (Astellas) VMS – Menopause NK3R antagonist Ph 3 NT-814 (KaNDy Therapeutics) VMS – Menopause NK1/3R antagonist Ph 2
Slide 38: Osanetant: Exclusivity / Timelines
Osanetant would be a New Chemical Entity (NCE) in the US, and as such would be eligible for five years’ market exclusivity from potential FDA approval Additional exclusivity (e.g. Orphan Drug Designation) will depend upon indication(s) and development pathway chosen Anticipate IND submission in 2H 2
Slide 39: ACER Financial Overview
Cash $16.1M as of September 30, 2019 Expected to have sufficient capital through end of 2020 Capitalization as of September 30, 2019 10.1M shares of common stock outstanding 11.5M shares of common stock fully diluted $87M invested through August 2018 financing ACER Financial Overview
Slide 40: Summary
Summary ACER Acer’s pipeline includes three clinical-stage product candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a taste-masked, immediate release formulation of sodium phenylbut
Acer Therapeutics — Investor Presentation (February 2020) on 6ix